Eton Pharmaceuticals Inc (NAS:ETON)

Q1 2026 Eton Pharmaceuticals Inc Earnings Call Transcript

May 14, 2026 / 08:30 PM GMT

Release Date Price: $29.96 (-2.79%)

Transcript 10-Q8-K

Key Points

Positve

Eton Pharmaceuticals Inc (ETON) achieved record product sales with a 73% year-over-year growth in product revenue.
The company launched two new major products, Desmoda and Hemangio, which are expected to contribute significantly to future revenue.
Eton Pharmaceuticals Inc (ETON) raised its full-year revenue guidance to exceed $120 million, up from the previous guidance of $110 million.
The company maintained a strong adjusted EBITDA margin of 24% for the quarter and expects to achieve a greater than 30% margin for the full year.
Eton Pharmaceuticals Inc (ETON) is advancing its R&D pipeline with several development milestones, including FDA clearance for a new clinical study and progress on multiple product development programs.

Negative

The launch of Hemangio is expected to have limited revenue contribution in the second quarter due to the mid-quarter launch and patient transfer complexities.
Approximately 60% to 65% of Hemangio's volume may be near zero revenue due to patient assistance programs and inherited payer contracts.
General and administrative expenses increased by 14% year-over-year, primarily due to higher FDA annual program fees.
The company faces challenges in transitioning thousands of patients to a new single pharmacy for Hemangio, which could impact the speed of revenue realization.
Eton Pharmaceuticals Inc (ETON) no longer qualifies for the orphan-PDUFA exemption, leading to increased costs.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ETON.OQ - Eton Pharmaceuticals Inc
Q1 2026 Eton Pharmaceuticals Inc Earnings Call
May 14, 2026 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon, and welcome to the Eaton Pharmaceuticals First Quarter 2026 Financial Results Conference Call.

At this time, all participants are on listen-only mode.

Following the full remarks, we'll open the call up for your questions.

Please be advised that this call is being recorded at the company's request.

At this time, I'd like to turn it over to David Krampa, Chief Business Officer at Enon Pharmaceuticals. Please proceed.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, operator. Good afternoon, everyone, and

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.